Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as herein, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by autotaxin.

Abstract: The present invention relates to novel pyridazines of the below formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by autotaxin:

Abstract: A method in a system comprising at least one portable data carrier, an authentication server and at least one reading device of at least one service provider which is couplable to the authentication server. The data carrier is adapted to communicate contactlessly with the reading device and comprises a security marking which can be read contactlessly by the reading device and on the basis of which the data carrier can be authenticated by the authentication server. The method comprises the step of equipping the data carrier with a data-carrier management marking that encodes a piece of data-carrier management information and readable contactlessly by a portable terminal. The method includes contactlessly reading out the data-carrier management marking by a portable terminal, transferring the data-carrier management information encoded in the data-carrier management marking to the authentication server, and managing the data carrier in the system employing the data-carrier management information.

Abstract: The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). The present description discloses the preparation of exemplary compounds (e.g. pages 37 to 45; examples 1.1 to 1.13) as well as relevant biological data thereof (e.g. pages 12 to 17, tables 1 to 9). An exemplary compound is e.g. 1-[4-(4-{1-[(6-{[6-(trifluoromethyl) pyridin-3-yl]methoxy}pyridazin-3-yl)amino]cyclopropyl}-phenyl) piperazin-1-yl]ethan-1-one (example 1.1).

Abstract: A method for managing portable data carriers in a system having at least one portable data carrier, an authentication server, and several service providers systems each including reading devices and a service provider unit. The reading devices may request an authentication information item of the data carrier and relay the authentication information item to the authentication server. The authentication server may authenticate the data carrier on the basis of the authentication information item and establish an application identity associated with the data carrier in the service provider system with the help of the security identity The established application identity associated with the data carrier may be transmitted from the authentication server to the reading device of the service provider system.

Abstract: The present invention relates to novel pyridazines according to formula (I) processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Abstract: A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=116; p=0.915).

Abstract: A method is disclosed for obtaining an antibody or antibody fragment to a conformational epitope specific for misfolded inactive human parathyroid hormone and fragments thereof. The method includes the steps of a) immunizing an animal with an immunogen which comprises oxidized parathyroid hormone or an oxidized fragment of parathyroid hormone, or both; and b) recovering an antibody, antibody fragments, or single chain antibody. The complementary determining region of the recovered antibody, antibody fragment or single chain antibody is capable of specifically recognizing a conformational epitope (antigenic determinant) which is present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone.

Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Abstract: A method in a system comprising at least one portable data carrier, an authentication server, and several service providers systems. The service provider systems have reading devices and a service provider unit. The method comprises the following steps: Requesting an authentication information item of the data carrier comprising a safety identity from the data carrier by a reading device of the service provider. Supplying the authentication information item by the data carrier to the reading device. Relaying the authentication information item by the reading device to the authentication server. Authenticating the data carrier by the authentication server on the basis of the authentication information item. Establishing an application identity associated with the data carrier in the service provider system by the authentication server with the help of the security identity. Transmitting the established application identity associated with the data carrier to the reading device of the service provider system.

Abstract: A method in a system comprising at least one portable data carrier, an authentication server and at least one reading device of at least one service provider which is couplable to the authentication server. The data carrier is adapted to communicate contactlessly with the reading device and comprises a security marking which can be read contactlessly by the reading device and on the basis of which the data carrier can be authenticated by the authentication server. The method comprises the step of equipping the data carrier with a data-carrier management marking that encodes a piece of data-carrier management information and readable contactlessly by a portable terminal. The method includes contactlessly reading out the data-carrier management marking by a portable terminal, transferring the data-carrier management information encoded in the data-carrier management marking to the authentication server, and managing the data carrier in the system employing the data-carrier management information.

Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.